TITLE

Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre

AUTHOR(S)
Tarricone, Ilaria; Casoria, Michela; Gozzi, Beatrice Ferrari; Grieco, Daniela; Menchetti, Marco; Serretti, Alessandro; Ujkaj, Manjola; Pastorelli, Francesca; Berardi, Domenico
PUB. DATE
January 2006
SOURCE
BMC Psychiatry;2006, Vol. 6, p11
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Second generation antipsychotics (SGA) have demonstrated several advantages over first generation antipsychotics (FGA) in terms of positive, negative, cognitive, and affective symptoms and a lower propensity for extrapyramidal side effects. Despite these undeniable advantages, SGA have been associated with causing and exacerbating metabolic disorders, such as obesity, diabetes, and hyperlipidemia. This cross sectional study aimed to evaluate the metabolic risk factor profile associated with use of SGAs in comparison with non-treated control patients. Methods: The study was carried out at a Community Mental Health Centre (CMHC) in Bologna. The study subjects were outpatients with serious mental disorders treated with SGA (clozapine, olanzapine, risperidone, quetiapine). A sample of adult men and women suffering from idiopathic hyperhydrosis, without psychiatric history or antipsychotic treatment, were randomly selected from outpatients of the Department of Neurology in Bologna as a reference group. We investigated differences among the treatment and reference groups for glycaemia, cholesterolaemia and triglyceridaemia levels. Results: The study sample was composed of 76 patients, 38 males and 38 females. The reference group was composed of 36 subjects, 19 females and 17 males. All patients treated with SGAs had higher mean glycaemia and triglyceridaemia and a significantly higher risk of receiving a diagnosis of hyperglycaemia and hypertriglyceridaemia than the reference group. We did not find any differences in mean glycaemia or mean triglyceridaemia levels among treatment groups. Patients with clozapine had a significantly higher mean BMI value and rate of obesity than patients treated with other SGAs. Conclusion: The rate of obesity and metabolic disorders observed in this study were higher than the prevalence in the control group and similar to that previously reported in psychiatric samples; these findings imply per se that more attention should be paid to the metabolic condition of psychiatric patients. In line with the International Consensus Conferences we recommend that monitoring of weight, fasting plasma glucose, cholesterol and triglyceride levels be obtained in routine clinical practice with all antipsychotics.
ACCESSION #
29323739

 

Related Articles

  • Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. Johnsen, Erik; A.^Kroken, Rune; Wentzel-Larsen, Tore; A.^Jørgensen, Hugo // BMC Psychiatry;2010, Vol. 10, p26 

    Background: No clear recommendations exist regarding which antipsychotic drug should be prescribed first for a patient suffering from psychosis. The primary aims of this naturalistic study were to assess the head-to-head effectiveness of first-line second-generation antipsychotics with regards...

  • List of Drugs in Development for Neurodegenerative Diseases. Pogačić, Vanda; Herling, Paul // Neurodegenerative Diseases;2007, Vol. 4 Issue 6, p443 

    Background/Aims: Alzheimer’s disease (AD) is characterized by extracellular Aβ peptide deposition originating from amyloid precursor protein cleavage and intracellular neurofibrillary tangles resulting from pathological tau protein aggregation. These processes are accompanied by...

  • Effects of long-term treatment with antipsychotics on serum leptin levels. Herrán, Andrés; García-Unzueta, María Teresa; Amado, José Antonio; de la Maza, María Teresa; Álvarez, Concepción; Vázquez-Barquero, José Luis; Herrán, A; García-Unzueta, M T; Amado, J A; de La Maza, M T; Alvarez, C; Vázquez-Barquero, J L // British Journal of Psychiatry;Jul2001, Vol. 179, p59 

    Background: Abnormal regulation of the adipocyte-derived hormone leptin could play a role in body weight gain induced by antipsychotics.Aims: To study the effects of long-term antipsychotic treatment on leptin levels in patients with schizophrenia.Method:...

  • Olanzapine and tardive dyskinesia. Woods, S. W. // British Journal of Psychiatry;Oct99, Vol. 175, p391 

    A letter to the editor is presented in response to the article "Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol," by C.M. Beasley and colleagues in volume 174.

  • Involvement of Basal Ganglia Network in Motor Disabilities Induced by Typical Antipsychotics. Chetrit, Jonathan; Ballion, Bérangère; Laquitaine, Steeve; Belujon, Pauline; Morin, Stéphanie; Taupignon, Anne; Bioulac, Bernard; Gross, Christian E.; Benazzouz, Abdelhamid // PLoS ONE;2009, Vol. 4 Issue 7, p1 

    Background: Clinical treatments with typical antipsychotic drugs (APDs) are accompanied by extrapyramidal motor sideeffects (EPS) such as hypokinesia and catalepsy. As little is known about electrophysiological substrates of such motor disturbances, we investigated the effects of a typical APD,...

  • Choking deaths: the role of antipsychotic medication. Ruschena, D.; Mullen, P. E.; Palmer, S.; Burgess, P.; Cordner, S. M.; Drummer, O. H.; Wallace, C.; Barry-Walsh, J. // British Journal of Psychiatry;Nov2003, Vol. 183, p446 

    Background: An increased risk of choking associated with antipsychotic medication has been repeatedly postulated.Aims: To examine this association in a large number of cases of choking deaths.Method: Cases of individuals who had died because of choking were...

  • Prevalence of obesity in patients receiving depot antipsychotics. Silverstone, T.; Smith, G.; Goodall, E. // British Journal of Psychiatry;Aug88, Vol. 153, p214 

    Antipsychotic drugs have long been noted to cause pronounced weight gain, and drug-induced obesity can assume major clinical importance in long-term medication in the management of chronic schizophrenia. Obesity is associated with increased morbidity and may reduce compliance, leading to a...

  • Increased mortality among elderly patients with dementia using atypical antipsychotics. Singh, Sonal; Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;8/2/2005, Vol. 173 Issue 3, p252 

    Discusses research being done on the use of atypical anti-psychotic drugs in the treatment of behavioral and psychological symptoms of dementia. Reference to a study by P. E. Lee, S. S. Freedman et al, published in the 2004 issue of the "British Medical Journal"; Incidence of death among...

  • Correlation of qEEG with PET in Schizophrenia. Alper, Kenneth; Günther, Wilfred; Prichep, Leslie S.; John, E. Roy; Brodie, Jonathan // Neuropsychobiology;1998, Vol. 38 Issue 1, p50 

    PET relative metabolism was correlated with quantitative EEG in 9 schizophrenic patients. The PET metabolic regions of interest were the frontal lobes, thalamus and basal ganglia, and right and left temporal lobes. Significant positive correlations were seen for the frontal lobes and delta EEG...

  • Haloperidol.  // AHFS Consumer Medication Information;May2020, p1 

    Haloperidol is used to treat psychotic disorders (conditions that cause difficulty telling the difference between things or ideas that are real and things or ideas that are not real). Haloperidol is also used to control motor tics (uncontrollable need to repeat certain body movements) and verbal...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics